Revenues

9 Months Ended

Sep. 30, 2019

Revenue from Contract with Customer [Abstract]

REVENUES

Disaggregation of Revenues

The following table disaggregates our product sales by product and geographic region and disaggregates our royalty, contract and other revenues by geographic region (in millions):



	Three Months Ended September 30, 2019									Three Months Ended September 30, 2018
	U.S.		Europe			Other Locations		Total		U.S.		Europe		Other Locations		Total
Product sales:
Atripla	$	132	$	10		$	7	$	149	$	221	$	29	$	8	$	258
Biktarvy	1,106		108			45		1,259		375		11		—		386
Complera/Eviplera	40		45			8		93		61		67		11		139
Descovy	256		63			44		363		310		81		15		406
Genvoya	761		152			65		978		921		203		52		1,176
Odefsey	317		111			8		436		323		95		5		423
Stribild	63		18			13		94		111		20		15		146
Truvada	688		14			19		721		665		62		30		757
Other HIV⁽¹⁾	3		1			1		5		10		2		2		14
Revenue share – Symtuza⁽²⁾	68		36			—		104		8		14		—		22
AmBisome	9		57			33		99		9		59		34		102
Ledipasvir/Sofosbuvir⁽³⁾	54		14			56		124		185		38		88		311
Letairis	121		—			—		121		241		—		—		241
Ranexa	31		—			—		31		178		—		—		178
Sofosbuvir/Velpatasvir⁽⁴⁾	282		118			116		516		225		136		116		477
Vemlidy	78		6			50		134		66		2		19		87
Viread	7		15			35		57		17		10		43		70
Vosevi	42		12			9		63		78		21		4		103
Yescarta	86		32			—		118		75		—		—		75
Zydelig	13		13			—		26		15		4		1		20
Other⁽⁵⁾	42		(21		)	4		25		37		19		8		64
Total product sales	4,199		804			513		5,516		4,131		873		451		5,455
Royalty, contract and other revenues	20		67			1		88		20		102		19		141
Total revenues	$	4,219	$	871		$	514	$	5,604	$	4,151	$	975	$	470	$	5,596



	Nine Months Ended September 30, 2019								Nine Months Ended September 30, 2018
	U.S.		Europe		Other Locations		Total		U.S.		Europe		Other Locations		Total
Product sales:
Atripla	$	387	$	52	$	33	$	472	$	723	$	119	$	79	$	921
Biktarvy	2,868		229		71		3,168		593		13		—		606
Complera/Eviplera	126		179		26		331		210		279		39		528
Descovy	735		200		128		1,063		895		234		41		1,170
Genvoya	2,222		522		229		2,973		2,678		596		144		3,418
Odefsey	865		328		27		1,220		905		230		15		1,150
Stribild	208		60		30		298		388		83		36		507
Truvada	1,896		88		61		2,045		1,821		245		108		2,174
Other HIV⁽¹⁾	23		3		11		37		30		6		10		46
Revenue share – Symtuza⁽²⁾	165		89		—		254		8		34		—		42
AmBisome	27		174		96		297		40		170		102		312
Ledipasvir/Sofosbuvir⁽³⁾	257		63		222		542		649		116		225		990
Letairis	522		—		—		522		689		—		—		689
Ranexa	205		—		—		205		581		—		—		581
Sofosbuvir/Velpatasvir⁽⁴⁾	731		428		341		1,500		733		502		278		1,513
Vemlidy	214		15		122		351		172		8		41		221
Viread	28		57		119		204		40		72		137		249
Vosevi	140		43		18		201		250		57		12		319
Yescarta	275		59		—		334		183		—		—		183
Zydelig	36		42		1		79		46		44		2		92
Other⁽⁵⁾	119		96		12		227		93		75		117		285
Total product sales	12,049		2,727		1,547		16,323		11,727		2,883		1,386		15,996
Royalty, contract and other revenues	61		181		5		247		54		233		49		336
Total revenues	$	12,110	$	2,908	$	1,552	$	16,570	$	11,781	$	3,116	$	1,435	$	16,332



____________________
Notes:
(1)	Includes Emtriva and Tybost
(2)	Represents our revenue from cobicistat (C), emtricitabine (FTC) and tenofovir alafenamide (TAF) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland UC
(3)	Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC
(4)	Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC
(5)	Includes Cayston, Hepsera and Sovaldi. Europe product sales included unfavorable adjustments recorded in 2019 for statutory rebates related to sales of Sovaldi made in prior years

Revenues Recognized from Performance Obligations Satisfied in Prior Periods

Revenues recognized from performance obligations satisfied in prior years related to royalties for licenses of our intellectual property were $201 million and $527 million for the three and nine months ended September 30, 2019, respectively, and $167 million and $395 million for the three and nine months ended September 30, 2018, respectively. Changes in estimates for variable consideration related to sales made in prior years resulted in a $9 million and $309 million increase in revenues for the three and nine months ended September 30, 2019, respectively. Changes in estimates for variable consideration related to sales made in prior years were not material for the three and nine months ended September 30, 2018, respectively.

Contract Balances

Our contract assets, which consist of unbilled amounts primarily from arrangements where the licensing of intellectual property is the only or predominant performance obligation, totaled $160 million and $125 million as of September 30, 2019 and December 31, 2018, respectively.

Contract liabilities were not material as of September 30, 2019 and December 31, 2018.